News & Links
Britannia Pharmaceuticals (part of the STADA Arzneimittel group of companies) has appointed Robert Wood as Marketing Director, for international markets.
For more information visit our news article
Experts at EFNS 2012 symposium believe earlier initiation of continuous dopaminergic stimulation (CDS) therapy is beneficial in advanced Parkinson's disease (PD). For more information visit our news article
Webinar with EURO-INF Project Leader Professor K Ray Chaudhuri discloses significant benefits of apomorphine and intrajejunal levodopa infusion in advanced Parkinson's disease. For more information visit our news article
APO-go®: simplifying the challenge of Parkinson’s therapy in advanced disease. For more information visit our news article
Our Japanese Partner, Kyowa Hakko Kirin Co,. Ltd, received confirmation of their Marketing Authorisation for apomorphine injection in Japan on 30th March 2012. For more information on Kyowa Hakko Kirin Co,. Ltd visit http://www.kyowa-kirin.co.jp/english/
New team members are now in place at Britannia Pharmaceuticals Limited. Our new Head of International Marketing Co-ordination, Veronica Guijarro joined Britannia in July 2011 relocating from her native Spain. Veronica has also lived and worked in Paris. Our new Director Partners Europe Middle East and Africa, Robert Wood joined in October 2011. Robert will be responsible for all facets of the Partner relationships in two continents. Both can be reached via the Contact Us page or on +44 1635 568400
February 2011- 2011 Exhibition programmed extended.
Britannia Pharmaceuticals Ltd are pleased to exhibit at two further meetings in 2011. We will be attending the 15th International Congress of Parkinson's Disease and Movement Disorders, taking place from 5th to 9th June in Toronto, Canada.
The website of this meeting is http://www.movementdisorders.org/congress/congress11
We will also exhibit at The XIX World Congress on Parkinson's Disease and Related Disorders organized by the Association of Parkinsonism and Related Disorders that will take place in Shanghai from 11th to 14th December 2011.
More details of this event can be found of the official website: http://www2.kenes.com/parkinson/Pages/Home.aspx
February 2011- Bio Europe Spring 2011.
March 14th to 16th, 2011 -
Milan, Italy - http://www.ebdgroup.com/bes
Meet us at Europe's Premier Business to Business Partnering event in March!
We're interested in learning more about your opportunities!
Please send us an invite via the Bio-Europe partneringONE® system!
January 2011- Expanding our partnership network.
Britannia Pharmaceuticals are pleased to announce that Care4Pharma have become our latest partner. Care4Pharma is the international roll-out of the Dutch company ApotheekZorg and is set to promote Britannia products across Switzerland.
This is a welcome return for some of Care4pharma's key personnel that have many years experience working as part of the APO family.
September 2010 - Bio Europe 2010
November 15–17, 2010 • Munich, Germany
Meet us at Europe’s Premier Business to Business Partnering event in November!
We’re interested in learning more about your opportunities!
Please send an us invite via the Bio-Europe partneringONE® system!
July 2010- 2011 Exhibition Programme
Britannia Pharmaceuticals Ltd have committed to exhibiting at two shows in the first quarter of 2011. We will be attending the 1st Meeting of WFN & ANEI Parkinson's Disease & Movement Disorders, taking place 8th-9th January 2011 at the Sheraton Hotel in Kolkata and the AOPMC 2011 show taking place March 25th-27th in Taipei. The website for the AOPMC Congress is:http://www.aopmc2011taiwan.com/
April 2010 - Meet Us in China!
We will be attending ChinaBio® Partnering Forum in Suzhou, China on June 23-24 2010. Send us a meeting request through the partnering system or email us in advance here
December 2009 - APO-hub launched. The hub for our apomorphine product has gone live at www.apo-hub.com, detailing what apomorphine is and basic information on Parkinson's Disease.
November 2009 - Britannia Pharmaceuticals has previously taken apomorphine nasal powder through to phase III clinical trials in patients with Parkinson’s disease. In these trials apomorphine nasal powder demonstrated clinical efficacy in relieving the ‘off’ periods of the mid to late stages of disease. Unfortunately the trials were stopped due to patient withdrawals as a result of reversible local irritation in the lower nostril.
Currently Britannia Pharmaceuticals has stopped development of apomorphine nasal powder but is interested to hear from parties that have a nasal delivery device that could prevent the accumulation of powder in the lower nose.